정규장
Log in Sign up
최근 시세가 확인되지 않는 종목 최근 5거래일간 시세가 수집되지 않았습니다. 거래 정지·상장 폐지 여부를 확인 중입니다.
COEP
COEP
Z Squared Inc
$16.40
+0.00 +0.00%

지 스퀘어드(COEP) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$81M
스몰캡
P/E
-
배당수익률
없음
52주 위치
67%
저점 +162% · 고점 -23%
애널리스트
적극 매수
B
Fundamental health
vs. Biotechnology 초소형주· based on 3 axes
수익성
산출 불가 (적자)
성장
Top 27%
밸류에이션
Top 20%
재무 안정
Top 59%
Index -P/E -EPS (ttm) -2.8Insider Own 39.53%Shs Outstand 5.8MPerf Week -
Market Cap 0.08BForward P/E -EPS next Y -Insider Trans -Shs Float 3.8MPerf Month 51.15%
Enterprise Value 0.08BPEG -EPS next Q -Inst Own 7.59%Short Float 11.43%Perf Quarter 54.57%
Income -0.01BP/S 59.4EPS this Y -Inst Trans 15.46%Short Ratio 8.07Perf Half Y 11.19%
Sales 0.00BP/B 5.46EPS next 5Y -ROA -70.73%Short Interest 0.43MPerf YTD 15.09%
Book/sh 3P/C 12.72EPS past 3/5Y 62.31% 40.22%ROE -96.83%52W High -23.4% ($21.41)Perf Year 31.52%
Cash/sh 1.29P/FCF -Sales past 3/5Y -ROIC -62.7%52W Low 161.98% ($6.26)Perf 3Y -35.43%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 50.41%Gross Margin -207.81%Volatility(W/M) 8.99% 8.52%Perf 5Y -91.69%
Dividend TTM -EV/Sales 55.3Sales Y/Y TTM -Oper. Margin -956.94%ATR (14) 1.09Perf 10Y -
Dividend Ex-Date -Quick Ratio 4.16EPS Q/Q 80.71%Profit Margin -800.38%RSI (14) 72.1Recom 1
Dividend Gr. 3/5Y -Current Ratio 4.16Sales Q/Q -SMA20 27.37% ($12.88)Beta -0.04Target Price $80
Payout -Debt/Eq 0.02Earnings -SMA50 33.77% ($12.26)Rel Volume 0Prev Close $16.4
Employees 6LT Debt/Eq 0.01EPS/Sales Surpr. -SMA200 20.77% ($13.58)Avg Volume(3M) 0.05MPrice $16.4
IPO 2020/12/17Option/Short No/NoTrades 0Volume -Change -
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Z Squared Inc (COEP) Investment Analysis

What kind of company is Z Squared Inc?

지 스퀘어드(COEP) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

⛏️ This is a transitioning company that has shifted its business focus from a cell therapy-centered biotech firm to a digital asset mining company. It has been restructured to secure mining capabilities for altcoins such as Litecoin, with Dogecoin as its primary focus, and is a micro-cap stock aimed at operating with its own facilities within the United States.

Market Cap
$0.1B
Approx. KRW 0.1 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank4669
Employees6people
IPO2020/12/17
Current Price$16.40 ≈ 22,468원
NASD · USA

Key Events

예정된 이벤트가 없습니다

COEP의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

  • 실적 발표는 보통 분기마다 있습니다
  • 배당주는 연 1~4회 배당락일이 있습니다
전체 경제/실적 캘린더 보기 →

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-956.9%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-800.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
-207.8%
✓ 부진
My positionBottom 25%
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Bottom 18%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-96.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-70.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-62.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.02
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
4.16
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
4.16
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$80.00
현재가 대비 +387.8%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+62.3%
우수
My positionTop 25%
Low range Average High range
방어주 초소형주 Median 30.0% · Top 25%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+40.2%
양호
My positionMid-range
Low range Average High range
방어주 초소형주 Median 16.4% · Top 29%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -160%p below the market
COEP -91.7% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-160.0%p
Significantly behind the market
vs Health Care (XLV)
-116.2%p
Significantly behind the sector average
1-year basis
vs S&P 500
+15.5%p
ahead of the market
vs Health Care (XLV)
+11.8%p
ahead of the sector average
Rank among peers
5-year return Upper-Mid (37%) Based on 245 peers
1-year return Top 17% Based on 315 peers
Current position within 52-week range
Low (-162.0%p) High (-23.4%p)
Current price is 162.0% above the 52-week low and 23.4% below the 52-week high
Recent risk (last 76 trading days)
Max drawdown
-26.5%
Annualized volatility
77.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 83-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-05-08
Uptrend zone

Current price $16.40 above the midline ($15.40). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

Current diagnosis · 2026-05-08
Death cross — bearish reversal signal

MACD(1.068) crossed below Signal(1.104). Trend reversal possible; read as a sell entry point.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️
Current diagnosis · 2026-05-08
Overbought zone — short-term pullback possible

RSI 72.1 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 65.5.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Assets·Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Pricey
🧾 Vs. Sales Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
5.46x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 초소형주 median 1.35x · Bottom 17% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
59.40x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Bottom 24% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$80.00 vs. current price +387.8%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership is broadly stable
Institutional net buying +15.5% · Short interest elevated 11.4% · Short interest up +4.0pp over last 76d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+15.5%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 7.6%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 39.5%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 52.9%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
11.4%
Somewhat high
Healthcare 초소형주 Median 3.9%
Past 76 days 📈 +4.0%p increase
Short interest days to cover
8.1 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 5.8M주
Float (tradable shares) 3.8M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 76 days.

ETFs holding COEP

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
COEP COEP This Stock
$80.8M- 5.5 -96.83% - +0.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 지 스퀘어드(COEP)?

지 스퀘어드(COEP) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of COEP?

The market cap of COEP is approximately $81M, ranking 4,669 within its sector.

What is the 52-week high and low for COEP?

COEP has recorded a 52-week high of $21.41 and a low of $6.26.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.